Company profile: CiMaas
1.1 - Company Overview
Company description
- Provider of immunotherapies engaging the immune system to treat cancers not cured by current standard of care, including CIM201 adoptive NK cell therapy using proprietary NK expansion for high cytotoxicity; CIM101 F012 feeder cells to rapidly expand NK cells under licensing; and CIM401 adoptive CAR-NK therapy targeting solid tumors, initially breast cancer.
Products and services
- CIM201: Adoptive NK cell therapy engineers expanded Natural Killer cells via proprietary expansion technology, achieving high cytotoxicity against various types of cancer by engaging the immune system
- CIM401: Adoptive CAR-NK cell therapy constructs Chimeric Antigen Receptor–modified NK cells to target solid tumors, initially focusing on breast cancer, in-development
- CIM101: Feeder cells for NK cell expansion supplies F012 feeder cells that rapidly expand NK cells for clinical applications under defined licensing conditions, licensable
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CiMaas
Mologen
HQ: Germany
Website
- Description: Provider of biopharmaceutical research and clinical development of innovative drugs for cancer and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mologen company profile →
Tubulis
HQ: Germany
Website
- Description: Provider of chemotherapeutic medications for cancer and chronic disorders, developing disease-matched protein-drug conjugates (ADCs) using proprietary P5 conjugation chemistry and the Tubutecan linker-payload platform. Products include TUB-030 targeting 5T4 in solid tumors for long-lasting anti-tumor activity and TUB-040 targeting NaPi2b in ovarian and lung cancer for stable, potent delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tubulis company profile →
Akari Therapeutics
HQ: United Kingdom
Website
- Description: Provider of clinical-stage therapeutics focused on development and commercialization of innovative treatments, including nomacopan, a bispecific recombinant inhibitor targeting complement C5 and LTB4 for autoimmune and inflammatory diseases; a Phase 3 HSCT-TMA program for pediatric and adult transplant-related thrombotic microangiopathy; and PAS-nomacopan, a long-acting candidate for geographic atrophy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akari Therapeutics company profile →
Kyverna Therapeutics
HQ: United States
Website
- Description: Provider of autologous and allogeneic anti-CD19 CAR T-cell therapies for B-cell-driven autoimmune diseases, including KYV-101 and KYV-201. Offers clinical trials in lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis, plus an expanded access program, using engineered T cells to potentially reset the immune system and achieve sustained remission.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kyverna Therapeutics company profile →
Kairos Therapeutics
HQ: Canada
Website
- Description: Provider of a proprietary next-generation antibody-drug conjugate platform as a biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kairos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CiMaas
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CiMaas
2.2 - Growth funds investing in similar companies to CiMaas
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CiMaas
4.2 - Public trading comparable groups for CiMaas
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →